CMPX vs. NAMS, IDYA, SDGR, TVTX, BLTE, VERA, IOVA, PRAX, GLPG, and WVE
Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Schrödinger (SDGR), Travere Therapeutics (TVTX), Belite Bio (BLTE), Vera Therapeutics (VERA), Iovance Biotherapeutics (IOVA), Praxis Precision Medicines (PRAX), Galapagos (GLPG), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.
Compass Therapeutics vs.
NewAmsterdam Pharma (NASDAQ:NAMS) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations.
NewAmsterdam Pharma's return on equity of 0.00% beat Compass Therapeutics' return on equity.
In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 4 articles in the media. NewAmsterdam Pharma's average media sentiment score of 0.71 beat Compass Therapeutics' score of 0.56 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.
NewAmsterdam Pharma has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.
NewAmsterdam Pharma currently has a consensus target price of $41.60, indicating a potential upside of 124.02%. Compass Therapeutics has a consensus target price of $11.29, indicating a potential upside of 286.50%. Given Compass Therapeutics' higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than NewAmsterdam Pharma.
Compass Therapeutics has lower revenue, but higher earnings than NewAmsterdam Pharma.
89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 28.5% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Compass Therapeutics received 11 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 76.09% of users gave Compass Therapeutics an outperform vote.
Summary
NewAmsterdam Pharma beats Compass Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Compass Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compass Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CMPX) was last updated on 2/21/2025 by MarketBeat.com Staff
Free CMPX Stock Alerts